Amgen Inc.'s and Johnson & Johnson's anemia drugs are tied to higher death risks or faster spreading tumors in eight trials when used at high doses, a finding that may require new restrictions, U.S. regulators said.
Amgen's Aranesp and Epogen and J&J's Procrit showed greater risks for patients with cancers of the breast, head and neck, lung, and cervix, said staff of the U.S. Food and Drug Administration, in briefing documents posted today on its Web site.
An FDA advisory panel will consider the benefits and risks of the products March 13 in a meeting in Gaithersburg, Maryland.
More at Bloomberg
1 comment:
Exactly when are these drugs going to be pulled from the market??
Drugs that kill more people than placebo GENERALLY (insert sarcasm here) shouldn't be on the market.
Post a Comment